Search

Your search keyword '"Mueller, Nicolas J."' showing total 675 results
Start Over Author "Mueller, Nicolas J." Publication Year Range Last 50 years
675 results on '"Mueller, Nicolas J."'

1. Infectious Diseases and Clinical Xenotransplantation

Author

Fishman, Jay A. and Mueller, Nicolas J.

Subjects
Xenotransplantation -- Usage -- Complications and side effects, Emerging communicable diseases -- Risk factors, Health, Usage, Complications and side effects, Risk factors
Abstract

Xenotransplantation, the implantation of vascularized organs or viable cells from nonhuman species into humans, is under development to address the shortage of human organs for transplantation. Clinical xenotransplantation from swine [...]

Published
2024
Full Text
View/download PDF

3. Infectious disease events in people with HIV receiving kidney transplantation: Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study

Author

Kusejko, Katharina, Kouyos, Roger D., Bernasconi, Enos, Boggian, Katia, Braun, Dominique L., Calmy, Alexandra, Cavassini, Matthias, van Delden, Christian, Furrer, Hansjakob, Garzoni, Christian, Hirsch, Hans H., Hirzel, Cedric, Manuel, Oriol, Schmid, Patrick, Khanna, Nina, Haidar, Fadi, Bonani, Marco, Golshayan, Dela, Dickenmann, Michael, Sidler, Daniel, Schnyder, Aurelia, Mueller, Nicolas J., Günthard, Huldrych F., and Schreiber, Peter W.

Published
2024
Full Text
View/download PDF

5. Invasive aspergillosis in liver transplant recipients in the current era

Author

Kimura, Muneyoshi, Rinaldi, Matteo, Kothari, Sagar, Giannella, Maddalena, Anjan, Shweta, Natori, Yoichiro, Phoompoung, Pakpoom, Gault, Emily, Hand, Jonathan, D’Asaro, Matilde, Neofytos, Dionysios, Mueller, Nicolas J., Kremer, Andreas E., Rojko, Tereza, Ribnikar, Marija, Silveira, Fernanda P., Kohl, Joshua, Cano, Angela, Torre-Cisneros, Julian, San-Juan, Rafael, Aguado, Jose Maria, Mansoor, Armaghan-e-Rehman, George, Ige Abraham, Mularoni, Alessandra, Russelli, Giovanna, Luong, Me-Linh, AlJishi, Yamama A., AlJishi, Maram N., Hamandi, Bassem, Selzner, Nazia, and Husain, Shahid

Published
2024
Full Text
View/download PDF

7. Surgical site infections after kidney transplantation are independently associated with graft loss

Author

Amico, Patrizia, Aubert, John-David, Banz, Vanessa, Beckmann, Sonja, Beldi, Guido, Berger, Christoph, Berishvili, Ekaterine, Berzigotti, Annalisa, Binet, Isabelle, Bochud, Pierre-Yves, Branca, Sanda, Bucher, Heiner, Catana, Emmanuelle, Cairoli, Anne, Chalandon, Yves, De Geest, Sabina, De Rougemont, Olivier, De Seigneux, Sophie, Dickenmann, Michael, Dreifuss, Joëlle Lynn, Duchosal, Michel, Fehr, Thomas, Ferrari-Lacraz, Sylvie, Garzoni, Christian, Golshayan, Déla, Goossens, Nicolas, Haidar, Fadi, Halter, Jörg, Heim, Dominik, Hess, Christoph, Hillinger, Sven, Hirsch, Hans H., Hirt, Patricia, Hoessly, Linard, Hofbauer, Günther, Huynh-Do, Uyen, Immer, Franz, Koller, Michael, Laesser, Bettina, Lamoth, Frédéric, Lehmann, Roger, Leichtle, Alexander, Manuel, Oriol, Marti, Hans-Peter, Martinelli, Michele, McLin, Valérie, Mellac, Katell, Merçay, Aurélia, Mettler, Karin, Mueller, Nicolas J., Müller-Arndt, Ulrike, Müllhaupt, Beat, Nägeli, Mirjam, Oldani, Graziano, Pascual, Manuel, Passweg, Jakob, Pazeller, Rosemarie, Posfay-Barbe, Klara, Rick, Juliane, Rosselet, Anne, Rossi, Simona, Rothlin, Silvia, Ruschitzka, Frank, Schachtner, Thomas, Schaub, Stefan, Scherrer, Alexandra, Schnyder, Aurelia, Schuurmans, Macé, Schwab, Simon, Sengstag, Thierry, Simonetta, Federico, Stampf, Susanne, Steiger, Jürg, Stirnimann, Guido, Stürzinger, Ueli, Van Delden, Christian, Venetz, Jean-Pierre, Villard, Jean, Vionnet, Julien, Wick, Madeleine, Wilhelm, Markus, Yerly, Patrick, Schreiber, Peter W., Hoessly, Linard D., Boggian, Katia, Neofytos, Dionysios, van Delden, Christian, Egli, Adrian, Hirzel, Cédric, Schmied, Bruno, Guerke, Lorenz, Matter, Maurice, de Rougemont, Olivier, Bonani, Marco, Sidler, Daniel, and Kuster, Stefan P.

Published
2024
Full Text
View/download PDF

8. Adjunctive glucocorticoid therapy for Pneumocystis jirovecii pneumonia in solid organ transplant recipients: A multicenter cohort, 2015-2020

Author

Hosseini-Moghaddam, Seyed M., Kothari, Sagar, Humar, Atul, Albasata, Hanan, Yetmar, Zachary A., Razonable, Raymund R., Neofytos, Dionysios, D’Asaro, Matilde, Boggian, Katia, Hirzel, Cedric, Khanna, Nina, Manuel, Oriol, Mueller, Nicolas J., Imlay, Hannah, Kabbani, Dima, Tyagi, Varalika, Smibert, Olivia C., Nasra, Mohamed, Fontana, Lauren, Obeid, Karam M., Apostolopoulou, Anna, Zhang, Sean X., Permpalung, Nitipong, Alhatimi, Hind, Silverman, Michael S., Guo, Henry, Rogers, Benjamin A., MacKenzie, Erica, Pisano, Jennifer, Gioia, Francesca, Rapi, Lindita, Prasad, G.V. Ramesh, Banegas, Marcela, Alonso, Carolyn D., Doss, Kathleen, Rakita, Robert M., and Fishman, Jay A.

Published
2024
Full Text
View/download PDF

9. BK polyomavirus serotype-specific antibody responses in blood donors and kidney transplant recipients with and without new-onset BK polyomavirus-DNAemia: A Swiss Transplant Cohort Study

Author

Amico, Patrizia, Bachofner, Adrian, Banz, Vanessa, Beckmann, Sonja, Beldi, Guido, Berger, Christoph, Berishvili, Ekaterine, Berzigotti, Annalisa, Binet, Françoise-Isabelle, Bochud, Pierre-Yves, Borner, Petra, Branca, Sanda, Cairoli, Anne, Catana, Emmanuelle, Chalandon, Yves, Compagnon, Philippe, De Geest, Sabina, De Seigneux, Sophie, Dickenmann, Michael, Dreifuss, Joëlle Lynn, Duchosal, Michel, Fehr, Thomas, Ferrari-Lacraz, Sylvie, Flammer, Andreas, Frossard, Jaromil, Golshayan, Dela, Goossens, Nicolas, Haidar, Fadi, Halter, Jürg, Hess, Christoph, Hillinger, Sven, Hirsch, Hans H., Hirt, Patricia, Hoessly, Linard, Hofbauer, Günther, Huynh-Do, Uyen, Immer, Franz, Khanna, Nina, Koller, Michael, Kremer, Andreas, Krueger, Thorsten, Kuhn, Christian, Laesser, Bettina, Lamoth, Frédéric, Lehmann, Roger, Leichtle, Alexander, L'Huillier, Arnaud, Manuel, Oriol, Marti, Hans-Peter, Martinelli, Michele, McLin, Valérie, Mellac, Katell, Merçay, Aurélia, Mettler, Karin, Müller, Nicolas, Müller, Jelena, Müller-Arndt, Ulrike, Nägeli, Mirjam, Neofytos, Dionysios, Nilsson, Jakob, Pascual, Manuel, Pazeller, Rosmarie, Reineke, David, Rick, Juliane, Rössler, Fabian, Rothlin, Silvia, Schachtner, Thomas, Schaub, Stefan, Schneidawind, Dominik, Schuurmans, Macé, Schwab, Simon, Sengstag, Thierry, Sidler, Daniel, Simonetta, Federico, Steiger, Jürg, Stirnimann, Guido, Stürzinger, Ueli, Van Delden, Christian, Venetz, Jean-Pierre, Villard, Jean, Vionnet, Julien, Wehmeier, Caroline, Wilhelm, Markus, Yerly, Patrick, Hillenbrand, Caroline A., Bani, Dorssa Akbari, Follonier, Océane, Kaur, Amandeep, Weissbach, Fabian H., Wernli, Marion, Wilhelm, Maud, Leuzinger, Karoline, Binet, Isabelle, Hirzel, Cédric, and Mueller, Nicolas J.

Published
2024
Full Text
View/download PDF

10. Outcome of Patients Transplanted for C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis

Author

Amico, Patrizia, Aubert, John-David, Banz, Vanessa, Beckmann, Sonia, Beldi, Guido, Berger, Christoph, Berishvili, Ekaterine, Binet, Isabelle, Bochud, Pierre-Yves, Branca, Sanda, Bucher, Heiner, Catana, Emmanuelle, Chalandon, Yves, De Geest, Sabina, De Seigneux Michael Dickenmann, Sophie, Dreifuss, Joëlle Lynn, Duchosal, Michel, Fehr, Thomas, Ferrari-Lacraz, Sylvie, Garzoni, Christian, Gaudet, Christophe, Golshayan, Déla, Goossens, Nicolas, Halter, Jörg, Heim, Dominik, Hess, Christoph, Hillinger, Sven, Hirsch, Hans H., Hirt, Patricia, Hofbauer, Günther, Huynh-Do, Uyen, Immer, Franz, Koller, Michael, Laager, Mirjam, Laesser, Bettina, Lamoth, Frédéric, Lehmann, Roger, Leichtle, Alexander, Manuel, Oriol, Marti, Hans-Peter, Martinelli, Michele, McLin, Valérie, Mellac, Katell, Mercay, Aurelia, Mettler, Karin, Mueller, Nicolas J., Müller, Antonia, Müller-Arndt, Ulrike, Müllhaupt, Beat, Nägeli, Mirjam, Oldani, Graziano, Pascual, Manuel, Passweg, Jakob, Posfay-Barbe, Klara, Rick, Juliane, Rosselet, Anne, Rossi, Simona, Rothlin, Silvia, Ruschitzka, Frank, Schachtner, Thomas, Schanz, Urs, Schaub, Stefan, Schwab, Simon, Schnyder, Aurelia, Schuurmans, Macé, Sengstag, Thierry, Simonetta, Federico, Steiger, Jürg, Stirniman, Guido, Stürzinger, Ueli, Van Delden, Christian, Venetz, Jean-Pierre, Villard, Jean, Vionnet, Julien, Wick, Madeleine, Wilhlem, Markus, Yerly, Patrick, Halfon, Matthieu, Taffé, Patrick, Bucher, Christian, Haidar, Fadi, Huynh-do, Uyen, Mani, Laila-Yasmin, Wehmeier, Caroline, Fakhouri, Fadi, and Golshayan, Dela

Published
2024
Full Text
View/download PDF

12. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

Author

Teh, Benjamin W, Mikulska, Malgorzata, Averbuch, Dina, de la Camara, Rafael, Hirsch, Hans H, Akova, Murat, Ostrosky-Zeichner, Luis, Baddley, John W, Tan, Ban Hock, Mularoni, Alessandra, Subramanian, Aruna K, La Hoz, Ricardo M, Marinelli, Tina, Boan, Peter, Aguado, Jose Maria, Grossi, Paolo A, Maertens, Johan, Mueller, Nicolas J, and Slavin, Monica A

Published
2024
Full Text
View/download PDF

13. Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates

Author

Sava, Mihaela, Bättig, Veronika, Gerull, Sabine, Passweg, Jakob R., Khanna, Nina, Garzoni, Christian, Gerber, Bernhard, Mueller, Nicolas J., Schanz, Urs, Berger, Christoph, Chalandon, Yves, van Delden, Christian, Neofytos, Dionysios, Stampf, Susanne, Franzeck, Fabian C., and Weisser, Maja

Published
2023
Full Text
View/download PDF

17. Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study.

Author

Amstutz, Alain, Chammartin, Frédérique, Audigé, Annette, Eichenberger, Anna L, Braun, Dominique L, Amico, Patrizia, Stoeckle, Marcel P, Hasse, Barbara, Papadimitriou-Olivgeris, Matthaios, Manuel, Oriol, Bongard, Cédric, Schuurmans, Macé M, Hage, René, Damm, Dominik, Tamm, Michael, Mueller, Nicolas J, Rauch, Andri, Günthard, Huldrych F, Koller, Michael T, and Schönenberger, Christof M

Subjects
SARS-CoV-2, COVID-19 vaccines, BOOSTER vaccines, CLINICAL trial registries, HIV
Abstract

Background Bivalent messenger RNA (mRNA) vaccines, designed to combat emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, incorporate ancestral strains and a new variant. Our study assessed the immune response in previously vaccinated individuals of the Swiss HIV Cohort Study (SHCS) and the Swiss Transplant Cohort Study (STCS) following bivalent mRNA vaccination. Methods Eligible SHCS and STCS participants received approved bivalent mRNA SARS-CoV-2 vaccines (mRNA-1273.214 or BA.1-adapted BNT162b2) within clinical routine. Blood samples were collected at baseline, 4 weeks, 8 weeks, and 6 months postvaccination. We analyzed the proportion of participants with anti-spike protein antibody response ≥1642 units/mL (indicating protection against SARS-CoV-2 infection), and in a subsample T-cell response (including mean concentrations), stratifying results by cohorts and population characteristics. Results In SHCS participants, baseline anti-spike antibody concentrations ≥1642 units/mL were observed in 87% (96/112), reaching nearly 100% at follow-ups. Among STCS participants, 58% (35/60) had baseline antibodies ≥1642 units/mL, increasing to 80% at 6 months. Except for lung transplant recipients, all participants showed a 5-fold increase in geometric mean antibody concentrations at 4 weeks and a reduction by half at 6 months. At baseline, T-cell responses were positive in 96% (26/27) of SHCS participants and 36% (16/45) of STCS participants (moderate increase to 53% at 6 months). Few participants reported SARS-CoV-2 infections, side-effects, or serious adverse events. Conclusions Bivalent mRNA vaccination elicited a robust humoral response in individuals with human immunodeficiency virus (HIV) or solid organ transplants, with delayed responses in lung transplant recipients. Despite a waning effect, antibody levels remained high at 6 months and adverse events were rare. Clinical Trials Registration. NCT04805125. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts

Author

Wright, Edwina J, Grund, Birgit, Robertson, Kevin R, Cysique, Lucette, Brew, Bruce J, Collins, Gary L, Poehlman-Roediger, Mollie, Vjecha, Michael J, Penalva de Oliveira, Augusto César, Standridge, Barbara, Carey, Cate, Avihingsanon, Anchalee, Florence, Eric, Lundgren, Jens D, Arenas-Pinto, Alejandro, Mueller, Nicolas J, Winston, Alan, Nsubuga, Moses S, Lal, Luxshimi, and Price, Richard W

Subjects
Infectious Diseases, HIV/AIDS, Clinical Research, Neurosciences, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, AIDS Dementia Complex, Adult, Anti-Retroviral Agents, CD4 Lymphocyte Count, Female, HIV Infections, Humans, Longitudinal Studies, Male, Secondary Prevention, Treatment Outcome, antiretroviral treatment, central nervous system, HAND, HIV, neurocognitive impairment, INSIGHT START Neurology Substudy Group, Biological Sciences, Medical and Health Sciences, Psychology and Cognitive Sciences, Virology
Abstract

ObjectiveTo compare the effect of immediate versus deferred antiretroviral treatment (ART) on neuropsychological test performance in treatment-naive HIV-positive adults with more than 500 CD4 cells/μl.DesignRandomized trial.MethodsThe START parent study randomized participants to commence immediate versus deferred ART until CD4 less than 350 cells/μl. The START Neurology substudy used eight neuropsychological tests, at baseline, months 4, 8, 12 and annually, to compare groups for changes in test performance. Test results were internally standardized to z-scores. The primary outcome was the average of the eight test z-scores (QNPZ-8). Mean changes in QNPZ-8 from baseline were compared by intent-to-treat using longitudinal mixed models. Changes from baseline to specific time points were compared using ANCOVA models.ResultsThe 592 participants had a median age of 34 years; median baseline CD4 count was 629 cells/μl; the mean follow-up was 3.4 years. ART was used for 94 and 32% of accrued person-years in the immediate and deferred groups, respectively. There was no difference between the immediate and deferred ART groups in QNPZ-8 change through follow-up [-0.018 (95% CI -0.062 to 0.027, P = 0.44)], or at any visit. However, QNPZ-8 scores increased in both arms during the first year, by 0.22 and 0.24, respectively (P

Published
2018

22. Burden, epidemiology, and outcomes of microbiologically confirmed respiratory viral infections in solid organ transplant recipients: a nationwide, multi-season prospective cohort study

Author

Mombelli, Matteo, Lang, Brian M., Neofytos, Dionysios, Aubert, John-David, Benden, Christian, Berger, Christoph, Boggian, Katia, Egli, Adrian, Soccal, Paola M., Kaiser, Laurent, Hirzel, Cédric, Pascual, Manuel, Koller, Michael, Mueller, Nicolas J., van Delden, Christian, Hirsch, Hans H., and Manuel, Oriol

Published
2021
Full Text
View/download PDF

23. Immunogenicity of High-Dose Versus MF59-Adjuvanted Versus Standard Influenza Vaccine in Solid Organ Transplant Recipients: The Swiss/Spanish Trial in Solid Organ Transplantation on Prevention of Influenza (STOP-FLU Trial)

Author

Swiss National Science Foundation, Sánchez-Céspedes, Javier [0000-0003-2707-1979], Mombelli, Matteo, Neofytos, Dionysios, Huynh-Do, Uyen, Sánchez-Céspedes, Javier, Stampf, Susanne, Golshayan, Dela, Dahdal, Suzan, Stirnimann, Guido, Schnyder, Aurelia, Garzoni, Christian, Venzin, Reto M., Magenta, Lorenzo, Schönenberger, Melanie, Walti, Laura, Hirzel, Cédric, Munting, Aline, Dickenmann, Michael, Koller, Michael, Aubert, John-David, Steiger, Jürg, Pascual, Manuel, Mueller, Thomas F., Schuurmans, Macé, Berger, Christoph, Binet, Isabelle, Villard, Jean, Mueller, Nicolas J., Egli, Adrian, Cordero, Van Delden, Christian, Manuel, Oriol, Swiss National Science Foundation, Sánchez-Céspedes, Javier [0000-0003-2707-1979], Mombelli, Matteo, Neofytos, Dionysios, Huynh-Do, Uyen, Sánchez-Céspedes, Javier, Stampf, Susanne, Golshayan, Dela, Dahdal, Suzan, Stirnimann, Guido, Schnyder, Aurelia, Garzoni, Christian, Venzin, Reto M., Magenta, Lorenzo, Schönenberger, Melanie, Walti, Laura, Hirzel, Cédric, Munting, Aline, Dickenmann, Michael, Koller, Michael, Aubert, John-David, Steiger, Jürg, Pascual, Manuel, Mueller, Thomas F., Schuurmans, Macé, Berger, Christoph, Binet, Isabelle, Villard, Jean, Mueller, Nicolas J., Egli, Adrian, Cordero, Van Delden, Christian, and Manuel, Oriol

Abstract

[Background] The immunogenicity of the standard influenza vaccine is reduced in solid-organ transplant (SOT) recipients, so new vaccination strategies are needed in this population., [Methods] Adult SOT recipients from 9 transplant clinics in Switzerland and Spain were enrolled if they were >3 months after transplantation. Patients were randomized (1:1:1) to a MF59-adjuvanted or a high-dose vaccine (intervention), or a standard vaccine (control), with stratification by organ and time from transplant. The primary outcome was vaccine response rate, defined as a ≥4-fold increase of hemagglutination-inhibition titers to at least 1 vaccine strain at 28 days postvaccination. Secondary outcomes included polymerase chain reaction–confirmed influenza and vaccine reactogenicity., [Results] A total of 619 patients were randomized, 616 received the assigned vaccines, and 598 had serum available for analysis of the primary endpoint (standard, n = 198; MF59-adjuvanted, n = 205; high-dose, n = 195 patients). Vaccine response rates were 42% (84/198) in the standard vaccine group, 60% (122/205) in the MF59-adjuvanted vaccine group, and 66% (129/195) in the high-dose vaccine group (difference in intervention vaccines vs standard vaccine, 0.20; 97.5% confidence interval [CI], .12–1); P < .001; difference in high-dose vs standard vaccine, 0.24 [95% CI, .16–1]; P < .001; difference in MF59-adjuvanted vs standard vaccine, 0.17 [97.5% CI, .08–1]; P < .001). Influenza occurred in 6% of the standard, 5% in the MF59-adjuvanted, and 7% in the high-dose vaccine groups. Vaccine-related adverse events occurred more frequently in the intervention vaccine groups, but most of the events were mild., [Conclusions] In SOT recipients, use of an MF59-adjuvanted or a high-dose influenza vaccine was safe and resulted in a higher vaccine response rate.

Published
2024

24. Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID‐19 prevention

Author

Trepl, Julia; https://orcid.org/0000-0001-8197-5595, Pasin, Chloé; https://orcid.org/0000-0001-8730-790X, Schneidawind, Dominik; https://orcid.org/0000-0002-2672-431X, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Bankova, Andriyana K; https://orcid.org/0000-0002-5072-9591, Abela, Irene A; https://orcid.org/0000-0002-5566-8628, Trepl, Julia; https://orcid.org/0000-0001-8197-5595, Pasin, Chloé; https://orcid.org/0000-0001-8730-790X, Schneidawind, Dominik; https://orcid.org/0000-0002-2672-431X, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Manz, Markus G; https://orcid.org/0000-0002-4676-7931, Bankova, Andriyana K; https://orcid.org/0000-0002-5072-9591, and Abela, Irene A; https://orcid.org/0000-0002-5566-8628

Abstract

Summary: Allogeneic haematopoietic cell transplantation (allo‐HCT) recipients exhibit an increased risk of COVID‐19, particularly in the early post‐transplant phase, due to insufficient vaccine responses. This retrospective study investigated the incidence of SARS‐CoV‐2 infection in allo‐HCT recipients who received tixagevimab/cilgavimab pre‐exposure prophylaxis (T/C PrEP) compared to those who did not. Logistic regression, adjusted for sex, age, SARS‐CoV‐2 vaccination status and immunosuppressive treatment, revealed a significant reduction in the likelihood of SARS‐CoV‐2 infection risk with T/C PrEP (adjusted odds ratio aOR = 0.26 [0.07, 0.91]). These findings suggest the potential efficacy of monoclonal antibody PrEP in protecting this vulnerable patient population from COVID‐19.

Published
2024

25. Do Infectious Diseases After Kidney Retransplantation Differ From Those After First Kidney Transplantation?

Author

Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, van Delden, Christian; https://orcid.org/0000-0002-2901-8285, Hirsch, Hans H; https://orcid.org/0000-0003-0883-0423, Meylan, Pascal, Boggian, Katia, Hirzel, Cédric; https://orcid.org/0000-0002-7870-912X, Garzoni, Christian; https://orcid.org/0000-0002-0832-2376, Sidler, Daniel; https://orcid.org/0000-0002-2435-5936, Schnyder, Aurelia, Schaub, Stefan; https://orcid.org/0000-0002-9170-1341, Golshayan, Déla, Haidar, Fadi, Bonani, Marco, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Schreiber, Peter W; https://orcid.org/0000-0001-8123-2601, Swiss Transplant Cohort Study, et al, Kusejko, Katharina; https://orcid.org/0000-0002-4638-1940, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, van Delden, Christian; https://orcid.org/0000-0002-2901-8285, Hirsch, Hans H; https://orcid.org/0000-0003-0883-0423, Meylan, Pascal, Boggian, Katia, Hirzel, Cédric; https://orcid.org/0000-0002-7870-912X, Garzoni, Christian; https://orcid.org/0000-0002-0832-2376, Sidler, Daniel; https://orcid.org/0000-0002-2435-5936, Schnyder, Aurelia, Schaub, Stefan; https://orcid.org/0000-0002-9170-1341, Golshayan, Déla, Haidar, Fadi, Bonani, Marco, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Schreiber, Peter W; https://orcid.org/0000-0001-8123-2601, Swiss Transplant Cohort Study, and et al

Abstract

Background Infectious diseases (IDs) are highly relevant after solid organ transplantation in terms of morbidity and mortality, being among the most common causes of death. Patients undergoing kidney retransplantation (re-K-Tx) have been already receiving immunosuppressive therapy over a prolonged period, potentially facilitating subsequent infections. Comparing ID events after re-K-Tx and first kidney transplantation (f-K-Tx) can delineate patterns and risks of ID events associated with prolonged immunosuppression. Methods We included adult patients with records on f-K-Tx and re-K-Tx in the Swiss Transplant Cohort Study. We analyzed ID events after f-K-Tx and re-K-Tx within the same patients and compared infection rates, causative pathogens, and infection sites. Recurrent time-to-event analyses were performed for comparison of infection rates. Results A total of 59 patients with a median age of 47 years (range, 18–73) were included. Overall, 312 ID events in 52 patients occurred. In multivariable recurrent event modeling, the rate of ID events was significantly lower after re-K-Tx (hazard ratio, 0.70; P = .02). More bacterial (68.9% vs 60.4%) and fungal (4.0% vs 1.1%) infections were observed after f-K-Tx but fewer viral infections (27.0% vs 38.5%) as compared with re-K-Tx (P = .11). After f-K-Tx, urinary and gastrointestinal tract infections were more frequent; after re-K-Tx, respiratory tract and surgical site infections were more frequent (P < .001). Conclusions ID events were less frequent after re-K-Tx. Affected sites differed significantly after f-K-Tx vs re-K-Tx.

Published
2024

26. Emergence of novel circoviruses in humans and pigs and their possible importance for xenotransplantation and blood transfusions

Author

Opriessnig, Tanja; https://orcid.org/0000-0001-9642-0904, Xiao, Chao‐Ting; https://orcid.org/0000-0001-5299-5650, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Denner, Joachim; https://orcid.org/0000-0003-3244-6085, Opriessnig, Tanja; https://orcid.org/0000-0001-9642-0904, Xiao, Chao‐Ting; https://orcid.org/0000-0001-5299-5650, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, and Denner, Joachim; https://orcid.org/0000-0003-3244-6085

Abstract

Background: As sequencing is becoming more broadly available, virus discovery continues. Small DNA viruses contribute to up to 60% of the overall virus load in pigs. Porcine circoviruses (PCVs) are small DNA viruses with a single‐stranded circular genome. They are common in pig breeds and have not been properly addressed for their potential risk in xenotransplantation. Whereas PCV1 is non‐pathogenic in pigs, PCV2 has been associated with various disease manifestations. Recently two new circoviruses have been described, PCV3 and PCV4. While PCV4 is currently present mainly in Asia, PCV3 is widely distributed, and has been identified in commercial pigs, wild boars, and pigs generated for xenotransplantation. In one case PCV3 was transmitted by pigs to baboons via heart transplantation. PCV3 pathogenicity in pigs was controversial initially, however, the virus was found to be associated with porcine dermatitis and nephropathy syndrome (PDNS), reproductive failure, and multisystemic inflammation. Inoculation studies with PCV3 infectious clones confirmed that PCV3 is pathogenic. Most importantly, recently discovered human circoviruses (CV) are closely related to PCV3. Methods: Literature was evaluated and summarized. A dendrogram of existing circoviruses in pigs, humans, and other animal species was created and assessed at the species level.ResultsWe found that human circoviruses can be divided into three species, human CV1, CV2, and CV3. Human CV2 and CV3 are closest to PCV3. Conclusions: Circoviruses are ubiquitous. This communication should create awareness of PCV3 and the newly discovered human circoviruses, which may be a problem for blood transfusions and xenotransplantation in immune suppressed individuals.

Published
2024

27. Immune monitoring-guided vs fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients. A Multicenter, Randomized Clinical Trial

Author

Manuel, Oriol; https://orcid.org/0000-0001-7607-0943, Laager, Mirjam, Hirzel, Cédric, Neofytos, Dionysios, Walti, Laura N, Hoenger, Gideon, Binet, Isabelle, Schnyder, Aurelia, Stampf, Susanne, Koller, Michael, Mombelli, Matteo, Kim, Min Jeong, Hoffmann, Matthias, Koenig, Katrin, Hess, Christoph, Burgener, Anne-Valérie, Cippà, Pietro E; https://orcid.org/0000-0002-9507-0057, Hübel, Kerstin, Mueller, Thomas F; https://orcid.org/0000-0003-2236-2312, Sidler, Daniel, Dahdal, Suzan, Suter-Riniker, Franziska, Villard, Jean, Zbinden, Andrea; https://orcid.org/0000-0001-8328-7614, Pantaleo, Giuseppe, Semmo, Nasser, Hadaya, Karine, Enríquez, Natalia, Meylan, Pascal R, Froissart, Marc, et al, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Manuel, Oriol; https://orcid.org/0000-0001-7607-0943, Laager, Mirjam, Hirzel, Cédric, Neofytos, Dionysios, Walti, Laura N, Hoenger, Gideon, Binet, Isabelle, Schnyder, Aurelia, Stampf, Susanne, Koller, Michael, Mombelli, Matteo, Kim, Min Jeong, Hoffmann, Matthias, Koenig, Katrin, Hess, Christoph, Burgener, Anne-Valérie, Cippà, Pietro E; https://orcid.org/0000-0002-9507-0057, Hübel, Kerstin, Mueller, Thomas F; https://orcid.org/0000-0003-2236-2312, Sidler, Daniel, Dahdal, Suzan, Suter-Riniker, Franziska, Villard, Jean, Zbinden, Andrea; https://orcid.org/0000-0001-8328-7614, Pantaleo, Giuseppe, Semmo, Nasser, Hadaya, Karine, Enríquez, Natalia, Meylan, Pascal R, Froissart, Marc, et al, and Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191

Abstract

BACKGROUND: The use of assays detecting cytomegalovirus (CMV)-specific T-cell-mediated immunity may individualize the duration of antiviral prophylaxis in transplant recipients. METHODS: In this open-label randomized trial, adult kidney and liver transplant recipients from six centers in Switzerland were enrolled if they were CMV-seronegative with seropositive donors or CMV-seropositive receiving anti-thymocyte globulins. Patients were randomized to a duration of antiviral prophylaxis based on immune-monitoring (intervention) or a fixed duration (control). Patients in the control group were planned to receive 180 days (CMV-seronegative) or 90 days (CMV-seropositive) of valganciclovir. Patients were assessed monthly with a CMV-specific interferon gamma release assay (T-Track® CMV); prophylaxis in the intervention group was stopped if the assay was positive. The primary outcomes were the proportion of patients with clinically significant CMV infection and reduction in days of prophylaxis. Between-group differences were adjusted for CMV serostatus. RESULTS: Overall, 193 patients were randomized (92 in the immune-monitoring and 101 in the control group) of which 185 had evaluation of the primary endpoint (87 and 98 patients, respectively). Clinically significant CMV infection occurred in 26/87 (adjusted percentage, 30.9%) in the immune-monitoring group and in 32/98 (adjusted percentage, 31.1%) in the control group (adjusted risk difference -0.1, 95%CI -13.0%, 12.7%; p = 0.064). The duration of antiviral prophylaxis was shorter in the immune-monitoring group (adjusted difference -26.0 days, 95%-CI -41.1 to -10.8 days, p < 0.001). CONCLUSIONS: Immune monitoring resulted in a significant reduction of antiviral prophylaxis, but we were unable to establish noninferiority of this approach on the co-primary endpoint of CMV infection.

Published
2024

28. Epidemiology, outcomes and risk factors for recurrence of Clostridioides difficile infections following allogeneic hematopoietic cell transplantation: a longitudinal retrospective multicenter study

Author

Ragozzino, Silvio; https://orcid.org/0000-0002-8100-2096, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Passweg, Jakob; https://orcid.org/0000-0001-7092-3351, Müller, Antonia, Medinger, Michael; https://orcid.org/0000-0003-0427-7747, Van Delden, Christian, Masouridi-Levrat, Stavroula; https://orcid.org/0000-0001-7502-5454, Chalandon, Yves; https://orcid.org/0000-0001-9341-8104, Tschudin-Sutter, Sarah, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, Swiss Transplant Cohort Study, Ragozzino, Silvio; https://orcid.org/0000-0002-8100-2096, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Passweg, Jakob; https://orcid.org/0000-0001-7092-3351, Müller, Antonia, Medinger, Michael; https://orcid.org/0000-0003-0427-7747, Van Delden, Christian, Masouridi-Levrat, Stavroula; https://orcid.org/0000-0001-7502-5454, Chalandon, Yves; https://orcid.org/0000-0001-9341-8104, Tschudin-Sutter, Sarah, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, and Swiss Transplant Cohort Study

Published
2024

29. Detection of Scedosporium spp.: Colonizer or pathogen? A retrospective analysis of clinical significance and management in a large tertiary centre

Author

Reinhold, Ilana; https://orcid.org/0000-0002-6222-0418, Quiblier, Chantal, Blaser, Frank, Bögeholz, Jan, Imkamp, Frank, Schuurmans, Macé M; https://orcid.org/0000-0001-5404-7566, Soyka, Michael B; https://orcid.org/0000-0003-4179-4989, Zbinden, Reinhard, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Reinhold, Ilana; https://orcid.org/0000-0002-6222-0418, Quiblier, Chantal, Blaser, Frank, Bögeholz, Jan, Imkamp, Frank, Schuurmans, Macé M; https://orcid.org/0000-0001-5404-7566, Soyka, Michael B; https://orcid.org/0000-0003-4179-4989, Zbinden, Reinhard, and Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191

Abstract

Infections with Scedosporium spp. are emerging in the past two decades and are associated with a high mortality rate. Microbiological detection can be associated with either a colonization or infection. Evolution from colonization into infection is difficult to predict and clinical management upon microbiological detection is complex. Microbiological samples from 2015 to 2021 were retrospectively analyzed in a single tertiary care centre. Classification into colonization or infection was performed upon first microbiological detection. Clinical evolution was observed until July 2023. Further diagnostic procedures after initial detection were analyzed. Among 38 patients with microbiological detection of Scedosporium spp.,10 were diagnosed with an infection at the initial detection and two progressed from colonization to infection during the observation time. The main sites of infections were lung (5/12; 41.6%) followed by ocular sites (4/12; 33.3%). Imaging, bronchoscopy or biopsies upon detection were performed in a minority of patients. Overall mortality rate was similar in both groups initially classified as colonization or infection (30.7% and 33.3% resp. (p=1.0)). In all patients where surgical debridement of site of infection was performed (5/12; 42%); no death was observed. Although death occurred more often in the group without eradication (3/4; 75%) compared with the group with successful eradication (1/8; 12.5%), statistical significance could not be reached (p=0.053). As therapeutic management directly impacts patients' outcome, a multidisciplinary approach upon microbiological detection of Scedosporium spp. should be encouraged. Data from larger cohorts are warranted in order to analyze contributing factors favoring the evolution from colonization into infection.

Published
2024

30. Immunogenicity of High-Dose vs. MF59-adjuvanted vs. Standard Influenza Vaccine in Solid Organ Transplant Recipients: The STOP-FLU trial

Author

Mombelli, Matteo, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Huynh-Do, Uyen, Sánchez-Céspedes, Javier, Stampf, Susanne, Golshayan, Dela, Dahdal, Suzan, Stirnimann, Guido, Schnyder, Aurelia, Garzoni, Christian, Venzin, Reto M, Magenta, Lorenzo, Schönenberger, Melanie, Walti, Laura, Hirzel, Cédric, Munting, Aline, Dickenmann, Michael, Koller, Michael, Aubert, John-David, Steiger, Jürg, Pascual, Manuel, Mueller, Thomas F, Schuurmans, Macé, Berger, Christoph, Binet, Isabelle, Villard, Jean, Mueller, Nicolas J, Egli, Adrian; https://orcid.org/0000-0002-3564-8603, Cordero, Elisa, van Delden, Christian, et al, Mombelli, Matteo, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Huynh-Do, Uyen, Sánchez-Céspedes, Javier, Stampf, Susanne, Golshayan, Dela, Dahdal, Suzan, Stirnimann, Guido, Schnyder, Aurelia, Garzoni, Christian, Venzin, Reto M, Magenta, Lorenzo, Schönenberger, Melanie, Walti, Laura, Hirzel, Cédric, Munting, Aline, Dickenmann, Michael, Koller, Michael, Aubert, John-David, Steiger, Jürg, Pascual, Manuel, Mueller, Thomas F, Schuurmans, Macé, Berger, Christoph, Binet, Isabelle, Villard, Jean, Mueller, Nicolas J, Egli, Adrian; https://orcid.org/0000-0002-3564-8603, Cordero, Elisa, van Delden, Christian, and et al

Abstract

BACKGROUND The immunogenicity of the standard influenza vaccine is reduced in solid-organ transplant (SOT) recipients, so that new vaccination strategies are needed in this population. METHODS Adult SOT recipients from nine transplant clinics in Switzerland and Spain were enrolled if they were >3 months after transplantation. High, with stratification by organ and time from transplant. The primary outcome was vaccine response rate, defined as a ≥4-fold increase of hemagglutination-inhibition titers to at least one vaccine strain at 28 days post-vaccination. Secondary outcomes included PCR-confirmed influenza and vaccine reactogenicity. RESULTS 619 patients were randomized, 616 received the assigned vaccines, and 598 had serum available for analysis of the primary endpoint (standard, n=198; MF59-adjuvanted, n=205; high-dose, n=195 patients). Vaccine response rates were 42% (84/198) in the standard vaccine group, 60% (122/205) in the MF59-adjuvanted vaccine group, and 66% (129/195) in the high-dose vaccine group (difference in intervention vaccines vs. standard vaccine, 0.20 [97.5% CI 0.12-1]; p<0.001; difference in high-dose vs. standard vaccine, 0.24 [95% CI 0.16-1]; p<0.001; difference in MF59-adjuvanted vs. standard vaccine, 0.17 [97.5% CI 0.08-1]; p<0.001). Influenza occurred in 6% the standard, 5% in the MF59-adjuvanted, and 7% in the high-dose vaccine groups. Vaccine-related adverse events occurred more frequently in the intervention vaccine groups, but most of the events were mild. CONCLUSIONS In SOT recipients, use of an MF59-adjuvanted or a high-dose influenza vaccine was safe and resulted in a higher vaccine response rate. TRIAL REGISTRATION Clinicaltrials.gov NCT03699839.

Published
2024

37. Donor‐derived infections: The Swiss perspective.

Author

Mueller, Nicolas J., Manuel, Oriol, and Hirzel, Cédric

Subjects
*COMMUNICABLE diseases, *COHORT analysis, *FACILITATED communication, *INFECTION, *TEAMS
Abstract

While Switzerland has not yet established a systematic approach, the small size of the country and the intensive collaboration between the transplant infectious disease teams facilitate a rapid communication once a donor‐derived infection is suspected. Critical information regarding donor infections is shared rapidly, and appropriate measures are discussed. The long‐term observational Swiss Transplant Cohort Study, which includes >92% of all solid organ recipients collects all relevant infectious disease episodes and facilitates detection of patterns of potential donor‐derived infection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients

Author

Quteineh, Lina, Wójtowicz, Agnieszka, Bochud, Pierre-Yves, Crettol, Severine, Vandenberghe, Frederik, Venetz, Jean-Pierre, Manuel, Oriol, Golshayan, Dela, Lehmann, Roger, Mueller, Nicolas J., Binet, Isabelle, van Delden, Christian, Steiger, Jürg, Mohacsi, Paul, Dufour, Jean-Francois, Soccal, Paola M., Kutalik, Zoltan, Marques-Vidal, Pedro, Vollenweider, Peter, Recher, Mike, Hess, Christoph, Pascual, Manuel, and Eap, Chin B.

Published
2019
Full Text
View/download PDF

41. Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID‐19 prevention.

Author

Trepl, Julia, Pasin, Chloé, Schneidawind, Dominik, Mueller, Nicolas J., Manz, Markus G., Bankova, Andriyana K., and Abela, Irene A.

Subjects
CELL transplantation, COVID-19, VACCINE effectiveness, PRE-exposure prophylaxis, VACCINATION status
Abstract

Summary: Allogeneic haematopoietic cell transplantation (allo‐HCT) recipients exhibit an increased risk of COVID‐19, particularly in the early post‐transplant phase, due to insufficient vaccine responses. This retrospective study investigated the incidence of SARS‐CoV‐2 infection in allo‐HCT recipients who received tixagevimab/cilgavimab pre‐exposure prophylaxis (T/C PrEP) compared to those who did not. Logistic regression, adjusted for sex, age, SARS‐CoV‐2 vaccination status and immunosuppressive treatment, revealed a significant reduction in the likelihood of SARS‐CoV‐2 infection risk with T/C PrEP (adjusted odds ratio aOR = 0.26 [0.07, 0.91]). These findings suggest the potential efficacy of monoclonal antibody PrEP in protecting this vulnerable patient population from COVID‐19. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Adjunctive glucocorticoid therapy for Pneumocystis jirovecii pneumonia in solid organ transplant recipients: A multicenter cohort, 2015-2020

Author

Hosseini-Moghaddam, Seyed M., primary, Kothari, Sagar, additional, Humar, Atul, additional, Albasata, Hanan, additional, Yetmar, Zachary A., additional, Razonable, Raymund R., additional, Neofytos, Dionysios, additional, D’Asaro, Matilde, additional, Boggian, Katia, additional, Hirzel, Cedric, additional, Khanna, Nina, additional, Manuel, Oriol, additional, Mueller, Nicolas J., additional, Imlay, Hannah, additional, Kabbani, Dima, additional, Tyagi, Varalika, additional, Smibert, Olivia C., additional, Nasra, Mohamed, additional, Fontana, Lauren, additional, Obeid, Karam M., additional, Apostolopoulou, Anna, additional, Zhang, Sean X., additional, Permpalung, Nitipong, additional, Alhatimi, Hind, additional, Silverman, Michael S., additional, Guo, Henry, additional, Rogers, Benjamin A., additional, MacKenzie, Erica, additional, Pisano, Jennifer, additional, Gioia, Francesca, additional, Rapi, Lindita, additional, Prasad, G.V. Ramesh, additional, Banegas, Marcela, additional, Alonso, Carolyn D., additional, Doss, Kathleen, additional, Rakita, Robert M., additional, and Fishman, Jay A., additional

Published
2023
Full Text
View/download PDF

44. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation

Author

Huang, Alice, Cicin-Sain, Caroline, Pasin, Chloe, Epp, Selina, Audigé, Annette, Müller, Nicolas J., Nilsson, Jakob, Bankova, Andriyana, Wolfensberger, Nathan, Vilinovszki, Oliver, Nair, Gayathri, Hockl, Philipp, Schanz, Urs, Kouyos, Roger D., Hasse, Barbara, Zinkernagel, Annelies S., Trkola, Alexandra, Manz, Markus G., Abela, Irene A., and Müller, Antonia M.S.

Published
2022
Full Text
View/download PDF

49. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

Author

Teh, Benjamin W, primary, Mikulska, Malgorzata, additional, Averbuch, Dina, additional, de la Camara, Rafael, additional, Hirsch, Hans H, additional, Akova, Murat, additional, Ostrosky-Zeichner, Luis, additional, Baddley, John W, additional, Tan, Ban Hock, additional, Mularoni, Alessandra, additional, Subramanian, Aruna K, additional, La Hoz, Ricardo M, additional, Marinelli, Tina, additional, Boan, Peter, additional, Aguado, Jose Maria, additional, Grossi, Paolo A, additional, Maertens, Johan, additional, Mueller, Nicolas J, additional, and Slavin, Monica A, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results